
Oncology NEWS International
- Oncology NEWS International Vol 6 No 7
- Volume 6
- Issue 7
Mucositis Pain Moderate After Transplant but Hard to Treat
NEW ORLEANS--Oral pain and mucositis occur predictably after bone marrow transplant for leukemia, and although the pain is usually described as mild to moderate, it is unlikely to be completely relieved, Deborah B. McGuire, PhD, of Emory University, said at the Oncology Nursing Society's 22nd Annual Congress.
NEW ORLEANS--Oral pain and mucositis occur predictably after bone marrowtransplant for leukemia, and although the pain is usually described asmild to moderate, it is unlikely to be completely relieved, Deborah B.McGuire, PhD, of Emory University, said at the Oncology Nursing Society's22nd Annual Congress.
The Emory study consisted of 18 cancer patients admitted for a bonemarrow transplant (14 patients) or high-dose chemotherapy (4 patients).Pain was assessed at four time intervals: baseline, during chemotherapy,seven days postchemo-therapy, and at least seven days postche-motherapy(to the study's end).
Two thirds of the patients reported pain at the third and fourth timeperiods (post-chemotherapy). Patients most commonly described the acuteoral pain as "tender, irritating, and sore." The pain variedin intensity from one interval to the next but never exceeded "moderate."
Despite numerous treatment strategies, the pain was only partially relieved,Dr. McGuire reported. Patients tended to use "mouth care" and"mental activity" as much as medication for pain relief, shesaid.
Mucositis was relatively mild, affecting mostly the lateral tongue andthe buccal and labial mucosa. It worsened at the two post-chemotherapytime points.
A Yale University Cancer Center study, also reported at the meeting,found that mucositis and oropharyngeal pain occurred in 83% of patientstreated for head and neck cancers with combination chemotherapy, most withradiation therapy as well.
Eighteen of the 35 patients in the study were hospitalized for dehydration,mucositis, and pain, said investigators Susan A. DiStasio, RN, and DennisL. Cooper, MD.
Supplemental nutrition was required by 60% of patients: 40% with a G-tubeand 20% with total parenteral nutrition. Mean weight loss for the patientswas 7.4 kg, peaking in the fifth week of radiotherapy.
Articles in this issue
over 28 years ago
Researchers Report Conflicting Data on Cervical Cancer in AIDSover 28 years ago
CIN Website Now Offers Daily Online Cancer Newspaperover 28 years ago
Members Sought for Director's Consumer Liaison Group: NCIover 28 years ago
Trial Attempts to Reverse Taxol Resistance in Ovarian Cancerover 28 years ago
Taxotere Bests Adriamycin in Metastatic Breast Cancerover 28 years ago
Antiemetic Tablets Prove Equal in Efficacy to IV Drug Regimenover 28 years ago
Preop Chemotherapy May Have Advantages in Primary Breast Cancerover 28 years ago
Doxorubicin Benefits Older Breast Cancer PatientsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































































